Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors.

Reproduction

School of Women's and Infants' HealthKing Edward Memorial Hospital, University of Western Australia, 374 Bagot Road, Subiaco, Perth, Western Australia 6008, AustraliaSchool of Medicine and PharmacologyRoyal Perth Hospital, University of Western Australia, 35 Stirling Highway, Crawley, Perth, Western Australia 6009, AustraliaSchool of Paediatrics and Child HealthTelethon Kids Institute, University of Western Australia, 100 Roberts Road, Subiaco, Perth, Western Australia 6008, AustraliaSchool of AnatomyPhysiology and Human Biology, University of Western Australia, 35 Stirling Highway, Crawley, Perth, Western Australia 6009, Australia.

Published: February 2015

AI Article Synopsis

  • The study investigated how fish oil-derived n-3 polyunsaturated fatty acids (PUFAs) during pregnancy affect the composition of placental fatty acids and related inflammatory gene expression.
  • Supplementation led to increased levels of docosahexaenoic acid (DHA) and specialized pro-resolving mediators (SPMs) precursors, but did not significantly impact eicosapentaenoic acid (EPA) levels or inflammatory gene expression in the placenta.
  • The findings suggest that while n-3 PUFA supplementation enhances certain placental lipid compositions, it does not seem to influence inflammatory responses, prompting further research into the role of SPMs and their potential effects on immune function in pregnancy.

Article Abstract

The aim of this study was to determine whether supplementation with fish oil-derived n-3 polyunsaturated fatty acids (n-3 PUFA) during pregnancy modifies placental PUFA composition, the accumulation of specialised pro-resolving lipid mediators (SPMs, specifically resolvins (Rv), protectins (PD) and upstream precursors) and inflammatory gene expression. Placentas were collected from women (n=51) enrolled in a randomised, placebo controlled trial of n-3 PUFA supplementation from 20-week gestation. Lipids were extracted for fatty acid analysis and SPMs were quantitated by mass spectrometry. Gene expression was determined by qRT-PCR. Using multiple regression analysis, data were correlated for placental n-3 PUFA and SPM levels with PUFA levels in maternal and cord blood erythrocytes. Supplementation with n-3 PUFAs increased placental docosahexaenoic acid (DHA) levels, but not eicosapentaenoic acid (EPA) levels (P<0.05), and increased the levels of the SPM precursors 18-hydroxyeicosapentaenoic acid and 17-hydroxydocosahexaenoic acid (17-HDHA) by two- to threefold (P<0.0005). RvD1, 17R-RvD1, RvD2 and PD1 were detectable in all placentas, but concentrations were not significantly increased by n-3 PUFA supplementation. Placental DHA levels were positively associated with maternal and cord DHA levels (P<0.005), and with placental 17-HDHA concentrations (P<0.0001). Placental mRNA expression of PTGS2, IL1β, IL6 and IL10 was unaffected by n-3 PUFA supplementation, but TNFα expression was increased by 14-fold (P<0.05). We conclude that n-3 PUFA supplementation in pregnancy i) enhances placental accumulation of DHA and SPM precursors, ii) does not alter placental EPA levels, and iii) has no stimulatory effects on inflammatory gene expression. Further studies are required to ascertain the biological significance of SPMs in the placenta and the potential immunomodulatory effects of elevating placental SPM levels.

Download full-text PDF

Source
http://dx.doi.org/10.1530/REP-14-0549DOI Listing

Publication Analysis

Top Keywords

n-3 pufa
12
fatty acid
8
pro-resolving lipid
8
lipid mediators
8
gene expression
8
n-3
6
pufa
5
effects maternal
4
maternal n-3
4
n-3 fatty
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!